A subtype of endometrial carcinoma with distinctive microscopic features and an unusually high rate of relapse.
Associated with more lymphatic invasion, deep myometrial invasion, lymph nodes metastases and worse outcome, even when statistically corrected for stage.
Resembles its ovarian counterpart in morphology and propensity for transperitoneal metastases.
Represents only 1-12% of endometrial carcinomas.
5-year survival rate 66%.
5-year survival for stage I disease 72%
5-year survival for stage II disease is 51%.
Often resistant to chemotherapy from onset, low response rates with chemotherapy, short response durations, and the five-year survival rate of 18% for stage IV disease.